Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


PD Dr. Dr. Udo Holtick has collaborated on the following programs:
Congress news 22/06/2020

EHA 25 European Perspectives Webinar: Multiple Myeloma & CAR-T

In this webinar, Prof. Dr. John Gribben, Prof. Dr. Valentín Ortiz and PD Prof. Dr. Dr. Udo Holtick discuss three practice changing studies on Multiple Myeloma/CAR-T. Study 1 summarised by Prof. Dr. John Gribben IXAZOMIB VS PLACEBO AS POST-INDUCTION MAINTENANCE THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) NOT UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT): PHASE 3 TOURMALINE-MM4 TRIAL Study 2 summarised by Prof. Dr. Valentín Ortiz IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121), A BCMA-TARGETED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: INITIAL KARMMA RESULTS Study 3 summarised by PD Prof. Dr. Dr. Udo Holtick LB2603 ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY   The webinar was independently produced and paid for by the MEDtalks Group of Companies.